小分子AMPK直接激动剂的最新研究进展

2型糖尿病是一种慢性代谢性疾病，其主要表现为高血糖和微血管并发症，是影响人类生活的重大疾病之一，目前尚理想的治疗药物。腺苷酸活化蛋白激酶(AMP-activated protein kinase，AMPK)是一种高度保守的丝氨酸/苏氨酸蛋白激酶，在细胞和机体能量代谢与平衡等方面发挥重要作用；小分子AMPK直接激动剂因在降低血糖方面的作用而有望成为新一代治疗2型糖尿病的药物。本文按结构分类，对近几年报道的小分子AMPK直接激动剂进行综述。
Type 2 diabetes, an epidemic disorder characterized by high blood glucose level associated with microvascular complications, is one of the main causes of human suffer across the globe, with no effective medicine up to now. AMP-activated protein kinase(AMPK), a highly conserved serine/threonine protein kinase, is a key sensor and regulator of intracellular and whole-body energy metabolism. Small molecule AMPK direct activators have been proven to lower blood-glucose, which is a promising candidate for the treatment of type 2 diabetes. The progress on the research of small molecule AMPK direct activators in recent years is summarized in this paper